World Pharma News Digest - 03.02.2014
7 views
Skip to first unread message
Ruslan David
Feb 3, 2014, 6:27:09 AM2/3/14
to worldph...@googlegroups.com
Body kills 'spontaneous' blood cancers on a daily basis
Immune cells undergo 'spontaneous' changes on a daily basis that could lead to cancers if not for the diligent surveillance of our immune system, Melbourne scientists have found. The research team from the Walter and Eliza Hall Institute found that the immune system was responsible for eliminating potentially cancerous immune B cells in their early stages, before they developed into B-cell lymphomas (also known as non-Hodgkin's lymphomas). The results of the study were published in the journal Nature Medicine.
Read more...
http://www.worldpharmanews.com/research/2689-body-kills-spontaneous-blood-cancers-on-a-daily-basis
Roche delivers strong 2013 results
Roche's Group sales rose 6% to 46.8 billion Swiss francs in 2013 as a result of strong demand for Roche's biologic medicines in the area of oncology, immunology and ophthalmology as well as for its clinical laboratory diagnostic products, especially immunoassays. This sales performance contributed significantly to an 8% increase in the Group's core operating profit and, combined with lower financing costs, a 10% rise in core earnings per share. IFRS net income rose 22% to 11.4 billion Swiss francs as a result of lower restructuring costs and the reversal of previous impairment charges.
Read more...
http://www.worldpharmanews.com/roche/2688-roche-delivers-strong-2013-results
Protein serves as a natural boost for immune system fight against tumors
Substances called adjuvants that enhance the body's immune response are critical to getting the most out of vaccines. These boosters stimulate the regular production of antibodies - caused by foreign substances in the body - toxins, bacteria, foreign blood cells, and the cells of transplanted organs.
Read more...
http://www.worldpharmanews.com/research/2687-protein-serves-as-a-natural-boost-for-immune-system-fight-against-tumors
UCB and Biogen Idec enter agreement to commercialize multiple sclerosis and hemophilia therapies in Asia
UCB and Biogen Idec today announced that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.
Read more...
http://www.worldpharmanews.com/ucb/2686-ucb-and-biogen-idec-enter-agreement-to-commercialize-multiple-sclerosis-and-hemophilia-therapies-in-asia
Pfizer reports fourth-quarter and full-year 2013 results
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2013. As a result of the full disposition of Zoetis on June 24, 2013, the financial results of the Animal Health business are reported as a discontinued operation in the consolidated statements of income for full-year 2013, and fourth-quarter and full-year 2012.
Read more...
http://www.worldpharmanews.com/pfizer/2685-pfizer-reports-fourth-quarter-and-full-year-2013-results
Melatonin shows potential to slow tumor growth in certain breast cancers
An early stage study shows melatonin - a hormone that regulates the body's sleep and awake cycles - may have the potential to help slow the growth of certain breast cancer tumors, according to researchers from Henry Ford Hospital in Detroit and Foundation for Research Support of the State of São Paulo.
Read more...
http://www.worldpharmanews.com/research/2684-melatonin-shows-potential-to-slow-tumor-growth-in-certain-breast-cancers
Novartis recognized among world's most sustainable companies in Corporate Knights Global 100
Novartis has been named among the 2014 Corporate Knights Global 100. Corporate Knights announced the results of its 2014 Global 100 Most Sustainable Corporations in the World (Global 100) index at the World Economic Forum in Davos.
Read more...
http://www.worldpharmanews.com/novartis/2683-novartis-recognized-among-worlds-most-sustainable-companies-in-corporate-knights-global-100
A silk coat for diamonds makes sleek new imaging and drug delivery tool
Silk and diamonds aren't just for ties and jewelry anymore. They're ingredients for a new kind of tiny glowing particle that could provide doctors and researchers with a novel technique for biological imaging and drug delivery. The new particles, just tens of nanometers across, are made of diamond and covered in silk.
Read more...
http://www.worldpharmanews.com/research/2682-a-silk-coat-for-diamonds-makes-sleek-new-imaging-and-drug-delivery-tool
PharmaNews.eu / Latest News
How an immune molecule makes cancer cells starve
http://www.pharmanews.eu/research-and-development/1396-how-an-immune-molecule-makes-cancer-cells-starve
Major EU research grant focused on stem cell-based treatment of Diabetes
http://www.pharmanews.eu/research-and-development/1395-major-eu-research-grant-focused-on-stem-cell-based-treatment-of-diabetes
Cracks in the cellular transport system can be key to a new generation of cancer therapies
http://www.pharmanews.eu/research-and-development/1394-cracks-in-the-cellular-transport-system-can-be-key-to-a-new-generation-of-cancer-therapies
Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF)
http://www.pharmanews.eu/novartis/1393-novartis-to-request-re-examination-of-serelaxin-rlx030-in-acute-heart-failure-ahf
Researchers discover simple amoeba holds the key to better treatment for Alzheimer's
http://www.pharmanews.eu/research-and-development/1392-researchers-discover-simple-amoeba-holds-the-key-to-better-treatment-for-alzheimers
ViiV Healthcare's new HIV medicine TivicayTM (dolutegravir) is approved in Europe
http://www.pharmanews.eu/gsk/1391--viiv-healthcares-new-hiv-medicine-tivicaytm-dolutegravir-is-approved-in-europe
Leaving home: Beta cells' way to maturity
http://www.pharmanews.eu/research-and-development/1389-leaving-home-beta-cells-way-to-maturity
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please download World Pharma News' Media Pack: http://www.worldpharmanews.com/contact-us
Immune cells undergo 'spontaneous' changes on a daily basis that could lead to cancers if not for the diligent surveillance of our immune system, Melbourne scientists have found. The research team from the Walter and Eliza Hall Institute found that the immune system was responsible for eliminating potentially cancerous immune B cells in their early stages, before they developed into B-cell lymphomas (also known as non-Hodgkin's lymphomas). The results of the study were published in the journal Nature Medicine.
Read more...
http://www.worldpharmanews.com/research/2689-body-kills-spontaneous-blood-cancers-on-a-daily-basis
Roche delivers strong 2013 results
Roche's Group sales rose 6% to 46.8 billion Swiss francs in 2013 as a result of strong demand for Roche's biologic medicines in the area of oncology, immunology and ophthalmology as well as for its clinical laboratory diagnostic products, especially immunoassays. This sales performance contributed significantly to an 8% increase in the Group's core operating profit and, combined with lower financing costs, a 10% rise in core earnings per share. IFRS net income rose 22% to 11.4 billion Swiss francs as a result of lower restructuring costs and the reversal of previous impairment charges.
Read more...
http://www.worldpharmanews.com/roche/2688-roche-delivers-strong-2013-results
Protein serves as a natural boost for immune system fight against tumors
Substances called adjuvants that enhance the body's immune response are critical to getting the most out of vaccines. These boosters stimulate the regular production of antibodies - caused by foreign substances in the body - toxins, bacteria, foreign blood cells, and the cells of transplanted organs.
Read more...
http://www.worldpharmanews.com/research/2687-protein-serves-as-a-natural-boost-for-immune-system-fight-against-tumors
UCB and Biogen Idec enter agreement to commercialize multiple sclerosis and hemophilia therapies in Asia
UCB and Biogen Idec today announced that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.
Read more...
http://www.worldpharmanews.com/ucb/2686-ucb-and-biogen-idec-enter-agreement-to-commercialize-multiple-sclerosis-and-hemophilia-therapies-in-asia
Pfizer reports fourth-quarter and full-year 2013 results
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2013. As a result of the full disposition of Zoetis on June 24, 2013, the financial results of the Animal Health business are reported as a discontinued operation in the consolidated statements of income for full-year 2013, and fourth-quarter and full-year 2012.
Read more...
http://www.worldpharmanews.com/pfizer/2685-pfizer-reports-fourth-quarter-and-full-year-2013-results
Melatonin shows potential to slow tumor growth in certain breast cancers
An early stage study shows melatonin - a hormone that regulates the body's sleep and awake cycles - may have the potential to help slow the growth of certain breast cancer tumors, according to researchers from Henry Ford Hospital in Detroit and Foundation for Research Support of the State of São Paulo.
Read more...
http://www.worldpharmanews.com/research/2684-melatonin-shows-potential-to-slow-tumor-growth-in-certain-breast-cancers
Novartis recognized among world's most sustainable companies in Corporate Knights Global 100
Novartis has been named among the 2014 Corporate Knights Global 100. Corporate Knights announced the results of its 2014 Global 100 Most Sustainable Corporations in the World (Global 100) index at the World Economic Forum in Davos.
Read more...
http://www.worldpharmanews.com/novartis/2683-novartis-recognized-among-worlds-most-sustainable-companies-in-corporate-knights-global-100
A silk coat for diamonds makes sleek new imaging and drug delivery tool
Silk and diamonds aren't just for ties and jewelry anymore. They're ingredients for a new kind of tiny glowing particle that could provide doctors and researchers with a novel technique for biological imaging and drug delivery. The new particles, just tens of nanometers across, are made of diamond and covered in silk.
Read more...
http://www.worldpharmanews.com/research/2682-a-silk-coat-for-diamonds-makes-sleek-new-imaging-and-drug-delivery-tool
PharmaNews.eu / Latest News
How an immune molecule makes cancer cells starve
http://www.pharmanews.eu/research-and-development/1396-how-an-immune-molecule-makes-cancer-cells-starve
Major EU research grant focused on stem cell-based treatment of Diabetes
http://www.pharmanews.eu/research-and-development/1395-major-eu-research-grant-focused-on-stem-cell-based-treatment-of-diabetes
Cracks in the cellular transport system can be key to a new generation of cancer therapies
http://www.pharmanews.eu/research-and-development/1394-cracks-in-the-cellular-transport-system-can-be-key-to-a-new-generation-of-cancer-therapies
Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF)
http://www.pharmanews.eu/novartis/1393-novartis-to-request-re-examination-of-serelaxin-rlx030-in-acute-heart-failure-ahf
Researchers discover simple amoeba holds the key to better treatment for Alzheimer's
http://www.pharmanews.eu/research-and-development/1392-researchers-discover-simple-amoeba-holds-the-key-to-better-treatment-for-alzheimers
ViiV Healthcare's new HIV medicine TivicayTM (dolutegravir) is approved in Europe
http://www.pharmanews.eu/gsk/1391--viiv-healthcares-new-hiv-medicine-tivicaytm-dolutegravir-is-approved-in-europe
Leaving home: Beta cells' way to maturity
http://www.pharmanews.eu/research-and-development/1389-leaving-home-beta-cells-way-to-maturity
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please download World Pharma News' Media Pack: http://www.worldpharmanews.com/contact-us
Reply all
Reply to author
Forward
0 new messages